{"filings":[{"id":1591877,"accession_number":"0001104659-26-082850","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2026-07-13T11:11:25+00:00","items":["7.01","9.01"],"status":"ready","headline":"Armata receives FDA agreement on pediatric study plan for AP-SA02 in S. aureus bacteremia","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA agreed on Initial Pediatric Study Plan (iPSP) for AP-SA02 as adjunct treatment for complicated S. aureus bacteremia in patients up to 17 years.","iPSP agreement is a regulatory requirement that must be met before submitting a Biologics License Application (BLA).","Pediatric studies will be deferred until adult Phase 3 safety/efficacy data are available; adult Phase 3 expected to start H2 2026.","CEO Dr. Deborah Birx highlighted the milestone as addressing vulnerable pediatric populations with limited treatment options.","AP-SA02 has QIDP and Fast Track designations; Phase 2a results presented at IDWeek 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1249876,"accession_number":"0001104659-26-077313","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K/A","filed_at":"2026-06-24T20:19:20+00:00","items":["5.02"],"status":"ready","headline":"Armata Pharmaceuticals appoints Dr. Daniel Gilmer to Nominating and Corporate Governance Committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Daniel Gilmer appointed to the Nominating and Corporate Governance Committee effective June 24, 2026.","Committee cash retainer set at $5,000, pro-rated from effective date.","Amendment to April 24, 2026 8-K that reported his board appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1204156,"accession_number":"0001104659-26-076627","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2026-06-23T11:10:57+00:00","items":["8.01","9.01"],"status":"ready","headline":"Armata Pharma receives $2.5M additional DoD funding for AP-SA02 Phase 3 readiness","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received $2.5M additional non-dilutive funding from U.S. DoD; total DoD award now $28.7M for AP-SA02 development.","Funding supports Phase 3 readiness of AP-SA02, a bacteriophage therapy for complicated Staphylococcus aureus bacteremia.","Company plans to initiate Phase 3 superiority study of AP-SA02 in H2 2026.","DoD funding provided via MTEC and managed by NMRC/NAMD; non-dilutive nature preserves shareholder value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1085277,"accession_number":"0001104659-26-074618","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2026-06-16T20:43:32+00:00","items":["5.07"],"status":"ready","headline":"Armata shareholders elect directors, approve advisory votes, ratify auditor at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven director nominees elected for one-year terms: Deborah Birx, Daniel Gilmer, Jules Haimovitz, Odysseas Kostas, Robin Kramer, Joseph Patti, Sarah Schlesinger.","Non-binding advisory vote on named executive officer compensation approved: 28,547,283 for, 27,765 against, 1,257,467 broker non-votes.","One-year frequency for future advisory votes on executive compensation selected: 28,567,809 for one year, 2,400 for two years.","Ratification of Ernst & Young as independent auditor for FY2026 passed: 29,842,514 for, 6,631 against, 0 broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":69161,"accession_number":"0001104659-26-060299","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2026-05-13T20:33:41+00:00","items":["1.01","2.02","2.03","7.01","9.01"],"status":"ready","headline":"Armata posts Q1 net loss of $115.3M ($3.16/diluted share); secures $25M Innoviva loan","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $115.3M vs $6.5M in Q1 2025; loss includes non-cash items from warrant amendments.","Revenue of $0.8M (grant) up from $0.5M; R&D spend $6.1M vs $5.4M; cash $4.8M down from $8.7M.","Entered $25M secured term loan with Innoviva at 14% interest, maturing Jan 11, 2029.","AP-SA02 Phase 3 superiority study in S. aureus bacteremia expected to start H2 2026; FDA granted QIDP and Fast Track.","Appointed Daniel Gilmer to Board; ~36.7M shares outstanding as of May 8, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99783,"accession_number":"0001104659-26-056658","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Armata receives FDA Fast Track for AP-SA02 phage therapy for S. aureus bacteremia","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Fast Track designation enables rolling BLA review and potential Accelerated Approval and Priority Review.","Phase 3 superiority study anticipated to begin in H2 2026.","AP-SA02 targets complicated bacteremia from MSSA and MRSA.","FDA designation underscores unmet need in severe, often deadly S. aureus infections."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99782,"accession_number":"0001104659-26-048997","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Armata appoints Dr. Daniel Gilmer to Board; option award for 51,280 shares","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Daniel Gilmer (39) appointed to Board effective April 24, 2026.","He will receive an option award to purchase 51,280 shares vesting over three years.","Non-management directors receive a cash retainer of $40,000 per year.","Gilmer is Senior Director at Pfizer and led the U.S. launch of PAXLOVID.","He is co-inventor of Streptococcus phage lysin exebacase (CF-301)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99781,"accession_number":"0001104659-26-039180","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Armata sets June 11, 2026 for annual meeting; record date April 17","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting scheduled for June 11, 2026 at 8:30 a.m. PT at Los Angeles headquarters.","Record date for voting entitlement is close of business on April 17, 2026.","Stockholder proposals and director nominations deadline: April 12, 2026 at 5:00 p.m. PT.","Proposals must be submitted in writing to the Corporate Secretary at the principal executive offices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115984,"accession_number":"0001104659-26-034523","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Armata Pharma Q4 net loss $124.3M on $105.8M non-cash fair value loss; going concern noted","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 grant revenue $1.1M vs $1.2M YoY; R&D expenses $6.1M vs $8.5M YoY.","Net loss $124.3M ($3.42/sh) vs net income $2.6M ($0.07/sh) in Q4 2024; includes $105.8M non-cash fair value loss on convertible loan.","Recognized $5.4M impairment expense on vacated Marina del Rey office lease.","Cash & equivalents $14.1M as of Dec 31 2025; amended debt agreements extending maturities to June 2027.","Audited 2025 financials include going concern qualification; ~36.6M shares outstanding as of Mar 18 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115983,"accession_number":"0001104659-26-031715","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Armata delays Q4/FY2025 earnings; FDA grants QIDP for phage candidate AP-SA02","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Will delay Q4/FY2025 financial results announcement; expects to file 10-K by March 31, 2026 due date.","FDA granted QIDP for AP-SA02 (S. aureus phage) as adjunct treatment for complicated bacteremia, adding Hatch-Waxman exclusivity.","FDA alignment reached on Phase 3 superiority study design; Armata plans to initiate study in H2 2026.","cGMP manufacturing facility in Los Angeles (~56,000 sq ft) formally commissioned; full production runs completed.","Phase 2a diSArm study showed higher cure rates with AP-SA02 plus antibiotics vs antibiotics alone; results presented at IDWeek 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115982,"accession_number":"0001104659-26-018333","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FDA grants QIDP designation to Armata's AP-SA02 for S. aureus bacteremia","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["AP-SA02 receives QIDP for intravenous adjunct treatment of complicated MSSA/MRSA bacteremia.","QIDP provides five-year Hatch-Waxman market exclusivity extension and eligibility for Fast Track.","CEO Dr. Deborah Birx says Phase 3 superiority study planned to start in H2 2026.","Company intends to submit a request for Fast Track Designation for AP-SA02 to FDA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115981,"accession_number":"0001104659-26-006446","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2026-01-26T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Armata extends credit maturity to June 2027 and warrants to Jan 2031 with Innoviva affiliate","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Maturity of four credit agreements with Innoviva Sub extended to June 1, 2027.","Expiration of four warrants to purchase ~10.65M shares extended to January 26, 2031.","Voting agreement termination date extended to earlier of Jan 2031 or FDA approval of any product candidate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115980,"accession_number":"0001104659-26-003076","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Armata Pharma receives FDA EOP2 support for AP-SA02 Phase 3 in S. aureus bacteremia","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA confirmed Phase 2a diSArm data support advancement of AP-SA02 to a Phase 3 superiority study.","Phase 3 study anticipated to initiate in the second half of 2026 in complicated S. aureus bacteremia.","First bacteriophage company to advance a clinical candidate to Phase 3 for this indication.","FDA is amenable to a request for Qualified Infectious Disease Product (QIDP) designation; Armata has submitted the request.","Partnership with U.S. Department of Defense and significant shareholder Innoviva continues."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132399,"accession_number":"0001104659-25-117387","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2025-12-01T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Armata enters ATM offering agreement for up to $100M of common stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Capital on Demand Sales Agreement with JonesTrading for at-the-market offering of common stock up to $100M.","JonesTrading will earn commission of up to 3.0% of gross proceeds; sales may be made on NYSE American.","Company not obligated to sell; Jones not obligated to buy; program entirely at Company's discretion.","Offered under existing S-3 registration statement (File No. 333-289585) and prospectus supplement dated Dec 1, 2025.","Agreement contains customary representations, warranties, and indemnification; either party may terminate on three days' notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132398,"accession_number":"0001104659-25-110351","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Armata Q3 loss from ops $7.8M; AP-SA02 Phase 2a shows efficacy, cGMP facility commissioned","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 grant revenue $1.2M (vs $3.0M prior year); R&D expense $5.8M (vs $9.5M).","Loss from operations $7.8M (vs $9.8M prior year); cash $14.8M as of Sep 30, 2025.","Phase 2a diSArm study: AP-SA02 + BAT had higher cure rate at day 12 vs BAT alone; 100% response without relapse.","56,000 sq ft cGMP manufacturing facility in Los Angeles fully commissioned; enables scale-up for late-stage trials.","Entered $15M secured credit agreement with Innoviva subsidiary, maturing January 2029, to fund AP-SA02 development."],"consensus_eps_estimate":-0.4284,"consensus_eps_actual":-1.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132397,"accession_number":"0001104659-25-101447","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Armata AP-SA02 phage cocktail hits primary endpoint in Phase 2a S. aureus bacteremia trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Day 12 clinical response 88% AP-SA02 vs 58% placebo (p=0.047) by blinded investigators; 83% vs 58% by adjudication committee.","Zero non-response/relapse in AP-SA02 arm at one week post-BAT and EOS vs ~25% placebo (p<0.025).","AP-SA02 well-tolerated; no serious adverse events related to study drug; TEAEs 6% AP-SA02 vs 0% placebo.","Armata plans to initiate a pivotal Phase 3 superiority trial in 2026, subject to FDA feedback.","Defined phage variants in AP-SA02 show intrinsic adaptive mechanism to patient isolates, may enhance efficacy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148963,"accession_number":"0001104659-25-089150","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Armata presents at H.C. Wainwright conference; no new data in exhibit","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["CEO Dr. Deborah Birx presented at H.C. Wainwright 27th Annual Global Investment Conference on Sept 10, 2025.","Exhibit 99.1 contains only title slide and forward-looking disclaimers; no new clinical or financial data.","Prior $26.2M DoD award referenced in disclaimers; no update on program milestones or guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148962,"accession_number":"0001558370-25-011227","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["1.01","2.02","2.03","7.01","9.01"],"status":"ready","headline":"Armata posts Q2 2025 operating loss; announces positive AP-SA02 trial results and $15M credit from Innoviva","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 operating loss of $6.8M vs. $11.9M loss in Q2 2024; cash at $4.3M as of June 30, 2025.","Entered $15M secured credit agreement with Innoviva at 14% interest, matures Jan 2029; proceeds to fund AP-SA02 development.","Positive topline results from Phase 1b/2a diSArm trial: met primary endpoints, improved clinical outcomes, no treatment-related SAEs.","Received additional $4.65M non-dilutive funding from U.S. Department of Defense through MTEC.","Plans end-of-Phase 2 meeting with FDA in H2 2025; expects to start Phase 3 pivotal trial in 2026."],"consensus_eps_estimate":-0.3978,"consensus_eps_actual":-0.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167909,"accession_number":"0001104659-25-059346","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Armata Pharma annual meeting results: board elected, compensation approved, auditor ratified","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Seven directors elected: Deborah L. Birx, Jules Haimovitz, Odysseas D. Kostas, Robin C. Kramer, Joseph M. Patti, Todd C. Peterson, Sarah Schlesinger — each for one-year term.","Non-binding advisory vote on named executive officer compensation approved: 30,180,386 for, 75,804 against, 31,922 abstentions.","Ratification of Ernst & Young as independent auditor for FY2025 approved: 31,471,009 for, 4,970 against, 2,147 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167908,"accession_number":"0001104659-25-050219","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Armata's AP-SA02 shows 100% clinical response in Phase 1b/2a S. aureus bacteremia trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoints met: safety, tolerability, and clinical response in ITT (n=50).","AP-SA02 + BAT achieved 100% clinical response at TOC for BAT and EOS vs 75% for placebo (p=0.017).","No treatment-related serious adverse events; two possibly related events (liver enzyme elevation, hypersensitivity).","At day 12, responder rate 88% AP-SA02 vs 58% placebo (p=0.047); MRSA patients had no relapse.","Company plans to initiate a pivotal trial as rapidly as possible."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167907,"accession_number":"0001558370-25-007752","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Armata Q1 net loss $6.5M, cash $11.7M; AP-SA02 Phase 1b/2a topline due H1 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss of $6.5M ($0.18 basic EPS) vs $25.0M loss in Q1 2024; includes $5.2M non-cash gain on convertible loan.","Cash and equivalents $11.7M at March 31, 2025, up from $9.3M at Dec 31, 2024; 36.2M shares outstanding.","Topline results from Phase 1b/2a diSArm study of intravenous AP-SA02 for S. aureus bacteremia expected in first half 2025.","Received additional $4.65M non-dilutive DoD/MTEC funding to support AP-SA02 Phase 2 close-out and FDA end-of-Phase 2 meeting.","Entered $10.0M secured credit agreement with Innoviva; existing Innoviva credit agreements extended to March 12, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167906,"accession_number":"0001104659-25-043017","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Armata receives $4.65M additional DoD funding for phage therapy trial; topline data Q2 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received $4.65M additional non-dilutive DoD funding for AP-SA02; total award now $26.2M.","Phase 1b/2a diSArm trial of AP-SA02 for S. aureus bacteremia enrolled 50 subjects; last visit Jan 2025.","Two subsets observed: one with in vivo phage amplification suggesting phage activity despite antibiotics.","Topline data expected in Q2 2025 to inform optimal dose for larger efficacy trial.","Going concern note in 2024 10-K remains unchanged per company disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167905,"accession_number":"0001104659-25-031127","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2025-04-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Armata Pharmaceuticals sets June 12, 2025 as annual meeting date","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting scheduled for June 12, 2025 at 8:30 a.m. PT in Los Angeles.","Record date for stockholders entitled to vote is April 17, 2025.","Advance notice deadline for stockholder proposals and director nominations is April 13, 2025 by 5:00 p.m. ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185147,"accession_number":"0001558370-25-003405","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2025-03-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Armata Q4 net income $2.6M; Phase 2 AP-PA02 positive; $10M credit deal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q4 net income $2.6M ($0.07 basic, -$0.23 diluted) vs net loss $19.8M YoY; includes $14.2M non-cash gain.","Phase 2 Tailwind study of inhaled AP-PA02 in NCFB showed statistically significant reduction of P.a. CFUs; well-tolerated.","Phase 1b/2a diSArm study of IV AP-SA02 for S. aureus bacteremia enrollment complete; topline data expected H1 2025.","Entered $10M secured credit agreement with Innoviva subsidiary at 14% interest, maturing March 2026; existing loans also extended."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185146,"accession_number":"0001104659-25-023015","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2025-03-12T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"Armata Pharma enters $10M secured credit agreement with Innoviva at 14% p.a., matures March 2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$10 million term loan from Innoviva at 14.0% annual interest, secured by substantially all assets.","Loan matures March 12, 2026; proceeds to fund development of phage candidates AP-PA02 and AP-SA02.","Amendments extend maturity of three prior Innoviva credit agreements also to March 12, 2026.","Innoviva is Armata's largest shareholder; loan guaranteed by domestic subsidiaries.","Company pursuing additional non-dilutive funding for late-stage trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201755,"accession_number":"0001104659-24-129981","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2024-12-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Armata Pharmaceuticals Announces Phase 2 Tailwind Study Results for Inhaled AP-PA02 in NCFB Subjects","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Post-hoc analysis showed statistically significant reduction of P.a. CFUs at day 17 (P=0.05) and day 24 (P=0.015).","Approximately one-third of AP-PA02 monotherapy subjects achieved at least a 2-log CFU reduction versus none on placebo.","Inhaled AP-PA02 was well-tolerated with mild, self-limiting adverse events; one possibly related serious adverse event reported.","AP-PA02 is a novel multi-phage therapeutic for chronic Pseudomonas aeruginosa infections in non-cystic fibrosis bronchiectasis.","Results suggest AP-PA02 monotherapy may be as effective as combination with anti-pseudomonal antibiotics in reducing lung P.a. burden."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201754,"accession_number":"0001104659-24-125505","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2024-12-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Armata Pharma CMO Mina Pastagia departs; separation agreement provides 12-month salary continuation","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Mina Pastagia terminated as Chief Medical Officer effective Nov 13, 2024; separation agreement executed Dec 2, 2024.","Agreement provides 12 months of base salary continuation, paid in equal installments starting ~60 days post-termination.","All unvested stock options and restricted stock units forfeited; vested options must be exercised within 90 days of separation.","Pastagia releases all claims against the company in exchange for the severance benefits."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201753,"accession_number":"0001104659-24-119701","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2024-11-15T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Armata extends debt maturity to Jan 2026, terminates CMO, hires senior finance and regulatory leaders","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended credit agreements with Innoviva; maturity moved to January 10, 2026.","Terminated Chief Medical Officer Mina Pastagia, M.D., effective Nov 13, 2024; eligible for 12 months base salary severance.","Hired David House as SVP Finance and Principal Financial Officer; hired Arwa Shurrab to lead regulatory strategy and operations.","Preparing for two potential Phase 3 licensure-supporting trials in 2025 with expanded clinical and regulatory team."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201752,"accession_number":"0001558370-24-015526","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Armata Pharma Q3 net loss $5.5M; Phase 2 Tail wind enrolled, topline data expected by year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $5.5M ($0.15/share) vs $31.2M loss in Q3 2023; includes $6.9M non-cash gain on convertible debt.","Grant revenue $3.0M (DoD/MTEC) vs $1.2M; R&D expense $9.5M; cash $17.1M as of Sep 30, 2024.","Phase 2 Tail wind (inhaled AP-PA02 for NCFB) enrollment complete; topline data expected by year-end 2024.","Phase 1b/2a diSArm (IV AP-SA02 for S. aureus bacteremia) enrollment complete; topline data Q1 2025.","Extended convertible debt and credit agreement maturity to Jan 10, 2026; appointed David House SVP Finance."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201751,"accession_number":"0001104659-24-116327","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Armata completes enrollment of Phase 1b/2a diSArm study of AP-SA02 for S. aureus bacteremia; topline Q1 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Full enrollment (n=50) achieved for intravenous AP-SA02 in Phase 1b/2a diSArm study targeting Staphylococcus aureus bacteremia.","Topline data expected in Q1 2025; if positive, may support initiation of a pivotal efficacy trial later in 2025.","Dose escalated to 5E10 PFU every 6 hours (2E11 PFU/24h) for 5 days without clinically significant adverse events.","Two blinded subsets observed: one showing evidence of in vivo phage amplification with detectable phage in blood.","Study supported by $21.6M in funding from Defense Health Agency and Joint Warfighter Medical Research Program via MTEC and NMRC-NAMD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201750,"accession_number":"0001104659-24-105853","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2024-10-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Armata Pharma VP Corporate Controller departs; receives base salary through Dec 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Richard Rychlik, VP Corporate Controller, employment ended September 30, 2024.","Separation agreement provides continued base salary through December 31, 2024.","Company also subsidizes COBRA premiums through December 31, 2024.","No successor or replacement officer has been named."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217753,"accession_number":"0001104659-24-103160","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2024-09-26T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Armata VP Corporate Controller Richard Rychlik to depart on Sept 30, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Richard Rychlik, VP and Corporate Controller, will leave Armata effective September 30, 2024.","Separation agreement terms are still being negotiated between Rychlik and the company.","No successor named; role of Corporate Controller is currently unstaffed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217752,"accession_number":"0001104659-24-092626","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2024-08-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Armata reports diSArm trial 80% enrolled, AP-PA02 topline data Sep 2024; Phase 3 planned for 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["diSArm Phase 1b/2a for AP-SA02 (S. aureus bacteremia) now 80% enrolled; completion expected Q4 2024.","AP-PA02 (P. aeruginosa bronchiectasis) enrollment completed; topline data expected September 2024.","Intravenous AP-SA02 and inhaled AP-PA02 well tolerated; early data show phage activity and persistence.","Phage candidates planned to enter pivotal Phase 3 trials in 2025, supported by $21.6M DoD grant.","Inhaled AP-PA02 monotherapy showed comparable to better bacterial load reduction vs antibiotics in blinded data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217751,"accession_number":"0001104659-24-090153","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2024-08-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Armata appoints David House as SVP, Finance and principal financial officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David House appointed SVP, Finance and principal financial officer, effective Aug. 16, 2024.","Base salary $350,000; target bonus 40% of base; option for 75,000 shares vesting over 4 years.","Previously Corporate Controller and VP of Accounting at ZO Skin Health (acquired by Blackstone).","Prior principal financial officer Richard Rychlik will remain as Corporate Controller."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217750,"accession_number":"0001558370-24-012055","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Armata Q2 operating loss $11.9M; AP-PA02 Phase 2 enrollment complete, topline H2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 operating loss $11.9M vs $9.6M in Q2 2023; R&D $8.5M, G&A $3.4M.","Cash and equivalents $26.4M as of June 30, 2024, up from $13.5M at Dec 31, 2023.","Completed enrollment in Phase 2 Tailwind study of inhaled AP-PA02; last patient visit Aug 7, topline data expected H2 2024.","Received $5.25M non-dilutive DoD grant for AP-SA02 diSArm Phase 2a study.","Built out cGMP manufacturing facility with five clean rooms, including fill-and-finish suite."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217749,"accession_number":"0001104659-24-082637","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2024-07-25T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Armata formalizes CMO Pastagia's salary at $456,800; improves severance to 12 months","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Pastagia's base salary confirmed at $456,800 (effective Jan 1, 2023).","Target bonus increased to 50% of salary for FY2024; no 2023 bonus awarded.","Eligible for annual equity grants starting 2025; current intent ~$300,000 fair value.","Severance extended from 6 to 12 months base salary for involuntary termination without cause.","Amendment also updates title to Chief Medical Officer (serving since Jan 1, 2023)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237654,"accession_number":"0001104659-24-071752","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Armata shareholders elect 7 directors, approve say-on-pay, ratify EY auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven director nominees elected: Deborah Birx, Jules Haimovitz, Odysseas Kostas, Robin Kramer, Joseph Patti, Todd Peterson, Sarah Schlesinger.","Non-binding advisory vote on executive compensation approved: 30,142,693 for, 55,393 against, 18,285 abstain.","Ratification of Ernst & Young as auditor for FY 2024 approved: 31,543,360 for, 20,716 against, 3,326 abstain.","Broker non-votes of 1,351,031 recorded on director elections and say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237653,"accession_number":"0001558370-24-007060","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Armata Pharma Q1 operating loss $10.2M; secures $35M loan at 14% from Innoviva","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Grant revenue $1.0M (up from $0.8M YoY); R&D expense $8.0M (down from $9.6M); G&A $3.2M (up from $2.5M).","Cash $37.9M as of March 31, 2024 vs $13.5M at Dec 31, 2023, aided by $35M credit agreement with Innoviva arm.","Loan bears 14% annual interest, matures June 4, 2025; principal and interest payable at maturity.","Phase 2a diSArm (AP-SA02) and Phase 2 Tail wind (AP-PA02) advancing; enrollment on track.","cGMP manufacturing build-out expected mid-2024; R&D labs and admin space already operational."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255183,"accession_number":"0001104659-24-037578","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2024-03-22T23:59:59+00:00","items":["5.08","9.01"],"status":"ready","headline":"Armata sets June 12, 2024 annual meeting; proposal deadline April 1","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting scheduled for June 12, 2024 at 8:30 a.m. PT via virtual webcast.","Record date for stockholders is April 19, 2024.","Deadline for Rule 14a-8 proposals and advance notice director nominations is April 1, 2024 at 5:00 p.m. ET.","Meeting date is more than 30 days later than the 2023 annual meeting, prompting new deadlines."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255182,"accession_number":"0001558370-24-003704","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Armata Pharma Q4 loss $9.6M; secures $35M loan at 14%, matures June 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 loss from operations $(9.6)M vs $(10.3)M in Q4 2022; cash $13.5M at Dec 31, 2023.","Entered $35M credit agreement with Innoviva SO on March 4, 2024; 14% annual rate, matures June 4, 2025.","Phase 2 diSArm study of AP-SA02 for Staph aureus bacteremia continues dose escalation; Phase 2 Tailwind study of AP-PA02 for NCFB progressing.","Manufacturing facility advanced; R&D labs completed; five cGMP suites expected H1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255181,"accession_number":"0001104659-24-030475","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2024-03-04T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Armata secures $35M secured term loan from Innoviva at 14% interest, maturity June 2025","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$35M loan from Innoviva Strategic Opportunities (Innoviva wholly-owned subsidiary, Armata's largest shareholder).","Interest rate 14.0% per annum, secured by substantially all company assets; maturity June 4, 2025.","Proceeds to fund Phase 2 trials of phage candidates AP-PA02 (Pseudomonas) and AP-SA02 (Staph aureus) and prepare for pivotal trials.","Amendments to July 2023 and January 2023 credit agreements with Innoviva to conform permitted debt and lien terms.","Loan guaranteed by domestic subsidiaries; customary affirmative/negative covenants and events of default."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272640,"accession_number":"0001558370-23-019016","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Armata Q3 loss from ops $(10.3)M; cash $24M; AP-SA02 and AP-PA02 enrollment accelerating","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Grant revenue $1.2M (vs $1.3M); R&D $8.0M (vs $8.4M); G&A $3.6M (vs $1.6M) due to one-time financing costs.","Loss from operations widened to $(10.3)M from $(8.6)M YoY.","Cash $24.0M as of Sept 30 vs $14.9M Dec 31, 2022; $25M credit agreement with Innoviva signed July 2023.","Phase 2a diSArm (AP-SA02) and Phase 2 Tailwind (AP-PA02) enrollment accelerating; expects Phase 2 diSArm completion in 2024.","Shares outstanding ~36.1M as of Nov 14, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289484,"accession_number":"0001104659-23-102132","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2023-09-20T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Armata promotes Rychlik to CFO; shareholders approve director elections and stock issuance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Richard Rychlik, Corporate Controller since Sept 5, promoted to principal financial officer, replacing Julianne Averill of Danforth Advisors who resigned as CFO.","Shareholders elected seven directors to one-year terms: Deborah Birx, Jules Haimovitz, Odysseas Kostas, Robin Kramer, Joseph Patti, Todd Peterson, Sarah Schlesinger.","Non-binding advisory vote on executive compensation approved: 29,620,537 for, 49,049 against, 14,773 abstentions.","Shareholders ratified Ernst & Young as independent auditor for FY2023: 30,850,478 for, 37,396 against.","Approved issuance of common stock upon conversion of loan from Innoviva Strategic Opportunities LLC under NYSE American rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289483,"accession_number":"0001104659-23-090888","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Armata appoints Dr. Deborah Birx as CEO, secures $25M credit from Innoviva","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Deborah L. Birx appointed CEO and Board member; former Innoviva Board member and world-renowned healthcare leader.","New $25M credit agreement with Innoviva; existing convertible credit maturity extended to Jan 10, 2025.","Q2 loss from operations $(9.6)M; cash $12.5M at June 30, 2023; 36.1M shares outstanding.","Phase 2 inhaled AP-PA02 in NCFB enrolling; AP-SA02 bacteremia study advancing to Phase 2a in 3Q23.","$16.3M total grant funding from DoD/MTEC for AP-SA02 program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289482,"accession_number":"0001104659-23-082362","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2023-07-19T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Armata Pharmaceuticals CEO Dr. Brian Varnum departs; severance includes 12-month salary continuation","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Brian Varnum's employment terminated July 10, 2023; separation agreement signed July 14, 2023.","Severance includes base salary continuation for 12 months and COBRA premium payments for up to 12 months.","Unvested options that would have vested within one year will vest on first anniversary; exercise extended to Sept 30, 2024.","Agreement includes non-disparagement, confidentiality, and reaffirmation of existing restrictive covenants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289481,"accession_number":"0001104659-23-079822","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2023-07-11T23:59:59+00:00","items":["1.01","2.03","5.02","8.01","9.01"],"status":"ready","headline":"Armata Pharma secures $25M loan from Innoviva, appoints Dr. Deborah Birx as CEO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enters $25M secured term loan with Innoviva Strategic Opportunities LLC at 14% interest, matures Jan 2025.","Extends existing convertible credit agreement maturity to Jan 2025 via amendment.","Terminates CEO Brian Varnum; appoints Dr. Deborah Birx, former White House Coronavirus Task Force coordinator, as CEO and director.","Proceeds to advance phage candidates AP-PA02 (Pseudomonas) and AP-SA02 (Staph) and build out cGMP manufacturing facility.","Resets 2023 annual meeting date from Aug 29 to Sep 14, 2023; record date unchanged at July 10, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310315,"accession_number":"0001104659-23-075279","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2023-06-27T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Armata sets 2023 annual meeting for Aug 29; proposal deadline July 7","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting on August 29, 2023, at 8:30 a.m. local time at principal offices in Marina del Rey, CA.","Record date for stockholders to vote is July 10, 2023.","Deadline for stockholder proposals under Rule 14a-8 and director nominations is July 7, 2023 at 5:00 p.m. ET.","Meeting date is more than 30 days from 2022 annual meeting, triggering new deadlines.","Proposals and nominations must be submitted in writing to the Corporate Secretary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310314,"accession_number":"0001104659-23-059297","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2023-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Armata Q1 loss widens to $11.3M; positive Ph1b/2a data for AP-PA02; closes $30M convertible","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Positive topline data from AP-PA02 Ph1b/2a in cystic fibrosis; first patient dosed in Phase 2 NCFB study.","AP-SA02 advanced: second cohort dosed in Staphylococcus aureus bacteremia Ph1b/2a; PJI study start-up activities.","Closed $30M secured convertible credit agreement with Innoviva (largest shareholder) to fund trials and manufacturing.","Q1 loss from operations $(11.3)M vs $(8.8)M a year ago; cash $25.1M vs $14.9M at Dec 31, 2022.","Grant revenue $0.8M from MTEC/DoD; $16.3M total grant funding expected for AP-SA02 program."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310313,"accession_number":"0001104659-23-056598","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2023-05-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Armata terminates CFO Erin Butler, appoints Julianne Averill as CFO via Danforth Advisors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Erin Butler terminated May 1, 2023 in connection with planned closure of San Diego office.","Julianne Averill appointed CFO effective May 2, 2023; serves as principal financial and accounting officer.","Averill, age 38, is a senior director at Danforth Advisors with 20+ years finance leadership.","Company pays Danforth $395/hour for Averill's services; no direct compensation to Averill."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328960,"accession_number":"0001558370-23-004017","cik":921114,"company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","form_type":"8-K","filed_at":"2023-03-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Armata reports Q4 2022 loss of $10.3M; positive phage trial data, $30M financing closed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["R&D expenses $9.6M in Q4 2022, up from $4.8M in Q4 2021, driven by clinical trial investment.","Cash $14.9M at Dec 31, 2022; closed $30M convertible credit with Innoviva in Q4.","Positive topline results from SWARM-P.a. Phase 1b/2a for AP-PA02 in CF patients; advancing to Phase 2b.","First patient dosed in Phase 2 NCFB study for AP-PA02; AP-SA02 bacteremia study first cohort completed.","Loss from operations $(10.3)M vs $(6.0)M in Q4 2021; grant revenue $1.1M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":294715458.11717695,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-03-16T23:59:59+00:00|328960"}